Literature DB >> 23916923

Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter.

Sanjiv J Shah1.   

Abstract

Entities:  

Keywords:  diastolic heart failure; heart rate; ivabradine; randomized controlled trials

Mesh：

Substances：

Year:  2013        PMID： 23916923      PMCID： PMC3842446          DOI： 10.1016/j.jacc.2013.07.010

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  20 in total

1.  Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.

Authors:  Viviane M Conraads; Marco Metra; Otto Kamp; Gilles W De Keulenaer; Burkert Pieske; José Zamorano; Panos E Vardas; Michael Böhm; Livio Dei Cas
Journal:  Eur J Heart Fail       Date:  2011-12-06       Impact factor: 15.534

2.  Trends in prevalence and outcome of heart failure with preserved ejection fraction.

Authors:  Theophilus E Owan; David O Hodge; Regina M Herges; Steven J Jacobsen; Veronique L Roger; Margaret M Redfield
Journal:  N Engl J Med       Date:  2006-07-20       Impact factor: 91.245

3.  Heart failure with preserved ejection fraction: treat now by treating comorbidities.

Authors:  Sanjiv J Shah; Mihai Gheorghiade
Journal:  JAMA       Date:  2008-07-23       Impact factor: 56.272

4.  Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

Authors:  Marco Guazzi; Marco Vicenzi; Ross Arena; Maurizio D Guazzi
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

5.  Evaluative framework for phase II studies in patients with heart failure and preserved ejection fraction.

Authors:  Mihai Gheorghiade; Muthiah Vaduganathan; Sanjiv J Shah
Journal:  JACC Heart Fail       Date:  2013-04-01       Impact factor: 12.035

6.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.

Authors:  William T Abraham; Philip B Adamson; Robert C Bourge; Mark F Aaron; Maria Rosa Costanzo; Lynne W Stevenson; Warren Strickland; Suresh Neelagaru; Nirav Raval; Steven Krueger; Stanislav Weiner; David Shavelle; Bradley Jeffries; Jay S Yadav
Journal:  Lancet       Date:  2011-02-19       Impact factor: 79.321

7.  Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum.

Authors:  Barry A Borlaug; Margaret M Redfield
Journal:  Circulation       Date:  2011-05-10       Impact factor: 29.690

8.  Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial.

Authors:  Dalane W Kitzman; Peter H Brubaker; Timothy M Morgan; Kathryn P Stewart; William C Little
Journal:  Circ Heart Fail       Date:  2010-09-17       Impact factor: 8.790

9.  Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction.

Authors:  Barry A Borlaug; Vojtech Melenovsky; Stuart D Russell; Kristy Kessler; Karel Pacak; Lewis C Becker; David A Kass
Journal:  Circulation       Date:  2006-11-06       Impact factor: 29.690

Review 10.  Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.

Authors:  Jan-Christian Reil; Gert-Hinrich Reil; Michael Böhm
Journal:  Trends Cardiovasc Med       Date:  2009-07       Impact factor: 6.677
View more
  29 in total

Review 1.  The pathophysiology of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

Review 2.  Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

Authors:  Kavita Sharma; David A Kass
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 3.  Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview.

Authors:  Sanjiv J Shah
Journal:  J Cardiovasc Transl Res       Date:  2017-06-05       Impact factor: 4.132

Review 4.  How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program.

Authors:  Sanjiv J Shah; Rebecca Cogswell; John J Ryan; Kavita Sharma
Journal:  Curr Cardiol Rep       Date:  2016-12       Impact factor: 2.931

5.  Pedal Edema as an Indicator of Early Heart Failure in the Community: Prevalence and Associations With Cardiac Structure/Function and Natriuretic Peptides (MESA [Multiethnic Study of Atherosclerosis]).

Authors:  Joseph Yeboah; Alain Bertoni; Waqas Qureshi; Shivani Aggarwal; Joao A C Lima; Nadine Kawel-Boehm; David A Bluemke; Sanjiv J Shah
Journal:  Circ Heart Fail       Date:  2016-12       Impact factor: 8.790

Review 6.  Phenotypic spectrum of heart failure with preserved ejection fraction.

Authors:  Sanjiv J Shah; Daniel H Katz; Rahul C Deo
Journal:  Heart Fail Clin       Date:  2014-05-22       Impact factor: 3.179

Review 7.  Heart failure with preserved ejection fraction in the elderly: scope of the problem.

Authors:  Bharathi Upadhya; George E Taffet; Che Ping Cheng; Dalane W Kitzman
Journal:  J Mol Cell Cardiol       Date:  2015-03-06       Impact factor: 5.000

8.  The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure.

Authors:  Mark A Peterzan; Oliver J Rider; Lisa J Anderson
Journal:  Card Fail Rev       Date:  2016-11

9.  Impact of right ventricular distensibility on congestive heart failure with preserved left ventricular ejection fraction in the elderly.

Authors:  Daisuke Harada; Hidetsugu Aasanoi; Ryuichi Ushijima; Takahisa Noto; Junya Takagawa; Hisanari Ishise; Hiroshi Inoue
Journal:  Heart Vessels       Date:  2017-12-13       Impact factor: 2.037

Review 10.  Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction.

Authors:  Debra D Dixon; Amar Trivedi; Sanjiv J Shah
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.